Thiotepa versus Bacille Calmette-Guérin in Non-Muscle Invasive Bladder Cancer

Fallah, Fatemeh; Fallah, Mahdi; Nia, Raheleh Sadat Sajadi

doi:10.1159/000343532

Cited by 6 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thiotepa has the beneficial effects of controlling ascites and preventing the recurrence of ovarian cancer. 30 , 31 Although it has been widely utilized to treat other malignancies, 32 – 34 gynecologic oncologists have paid little attention to this agent for over 10 years, possibly due to the dominance of the standard chemotherapy, platinum/taxane, in ovarian cancer. However, bevacizumab and thiotepa were administered to only 6 and 11 patients in our series, respectively.…”

Section: Discussionmentioning

confidence: 99%

Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

The purpose of this study was to evaluate the effects of salvage chemotherapy on recurrent or persistent ovarian clear cell carcinoma (CCC) with the goal of identifying a more rational treatment regimen for this lethal disease.The medical records of patients with CCC were retrospectively reviewed to select patients that were subsequently treated for recurrent or persistent disease.Of the 164 women with recurrent or persistent CCC, 485 chemotherapy courses with 1766 cycles were administered. Overall, the clinical benefit rate (CBR) was 39.4%, and the mean progression-free survival (PFS) was 4.5 months. Grade 3/4 toxicities occurred in 94 courses (19.4%). The CBR for TC was 45.1%, with a PFS of 3.7 months. Compared to that of TC, the CBRs for PC and CC were significantly lower (P = 0.020 and 0.021, respectively). The CBRs and PFS for PAF-C were slightly higher (P = 0.518 and 0.077, respectively), but showed a significantly higher adverse event rate (AER, P = 0.039). The CBR for bevacizumab was 50% with an extraordinarily long PFS (49.8 months). Gemcitabine and oxaliplatin had similar values for CBRs (44.4% and 44.1%) and PFS (2.5 and 3.4 months), respectively. Docetaxel (weekly) exhibited a notably low AER of 2.7%, and topotecan was associated with a relatively long PFS (7.7 months).For cis/carboplatin-pretreated patients, the existing active agents, such as oxaliplatin, gemcitabine, topotecan, and especially bevacizumab, are promising. Docetaxel (weekly) is well tolerated and might offer a particularly viable option for heavily pretreated patients. However, additional research to identify for a continued search for the optimal combination of chemotherapeutics or novel agents is still warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Here, to illustrate the proposed method, we focus on making inferences about the time to first tumor recurrence. Although the number of recurrent tumors occurring between clinical visits can be used as an indicator of tumor progression, the time to the first tumor recurrence provides the physicians another medical point of view about the effect of treatment on disease-free survival time at the beginning of cancer therapy [26,27].…”

Section: Discussionmentioning

confidence: 99%

Semiparametric regression analysis of failure time data with dependent interval censoring

Chen¹,

Shen

2017

Statistics in Medicine

View full text Add to dashboard Cite

Interval-censored failure-time data arise when subjects are examined or observed periodically such that the failure time of interest is not examined exactly but only known to be bracketed between two adjacent observation times. The commonly used approaches assume that the examination times and the failure time are independent or conditionally independent given covariates. In many practical applications, patients who are already in poor health or have a weak immune system before treatment usually tend to visit physicians more often after treatment than those with better health or immune system. In this situation, the visiting rate is positively correlated with the risk of failure due to the health status, which results in dependent interval-censored data. While some measurable factors affecting health status such as age, gender, and physical symptom can be included in the covariates, some health-related latent variables cannot be observed or measured. To deal with dependent interval censoring involving unobserved latent variable, we characterize the visiting/examination process as recurrent event process and propose a joint frailty model to account for the association of the failure time and visiting process. A shared gamma frailty is incorporated into the Cox model and proportional intensity model for the failure time and visiting process, respectively, in a multiplicative way. We propose a semiparametric maximum likelihood approach for estimating model parameters and show the asymptotic properties, including consistency and weak convergence. Extensive simulation studies are conducted and a data set of bladder cancer is analyzed for illustrative purposes. Copyright © 2017 John Wiley & Sons, Ltd.

show abstract

“…Seven of the 59 studies identified in the HRQoL SLR reported the symptoms experienced by patients with NMIBC prior to receiving any treatment. [17][18][19][20][21][22][23] Three were retrospective database studies, 19,21,22 two were patient surveys, 17,23 one was a prospective observational study, 18 and one was an RCT. 20 The most frequently reported symptoms across the seven studies were hematuria, dysuria, frequent urination, and urgency (Table 1).…”

Section: Symptom Burden Prior To Treatmentmentioning

confidence: 99%

“…[17][18][19][20][21][22][23] Three were retrospective database studies, 19,21,22 two were patient surveys, 17,23 one was a prospective observational study, 18 and one was an RCT. 20 The most frequently reported symptoms across the seven studies were hematuria, dysuria, frequent urination, and urgency (Table 1). 17,18,[20][21][22][23][24] Among patients with high-risk NMIBC disease, the overall symptom burden prior to treatment was worse for younger patients aged <65 years than those ≥65 years, and worse for women than men.…”

Section: Symptom Burden Prior To Treatmentmentioning

confidence: 99%

“…20 The most frequently reported symptoms across the seven studies were hematuria, dysuria, frequent urination, and urgency (Table 1). 17,18,[20][21][22][23][24] Among patients with high-risk NMIBC disease, the overall symptom burden prior to treatment was worse for younger patients aged <65 years than those ≥65 years, and worse for women than men. 18 ClinicoEconomics and Outcomes Research 2020:12 submit your manuscript | www.dovepress.com…”

Section: Symptom Burden Prior To Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

<p>Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews</p>

Lee¹,

Kwon²,

Forsythe³

et al. 2020

CEOR

View full text Add to dashboard Cite

Purpose: Non-muscle invasive bladder cancer (NMIBC) is a malignancy restricted to the inner lining of the bladder. Intravesical Bacillus Calmette-Guerin (BCG) following transurethral resection of the bladder tumor is the mainstay first-line treatment for high-risk NMIBC patients. Two systematic literature reviews (SLRs) were conducted to further assess the current evidence on BCG use in NMIBC and the humanistic and economic burden of disease. Methods: Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, Embase ® and MEDLINE ® were searched using the Ovid platform to identify interventional or real-world evidence studies on the health-related quality of life (HRQoL) and economic burden in NMIBC. Limited evidence was found from initial economic SLR searches in NMIBC, so additional targeted searches for bladder cancer were conducted to expand findings. Results: Fifty-nine publications were included in the HRQoL SLR, of which 23 reported HRQoL and symptoms in NMIBC. At diagnosis, HRQoL was comparable with population norms but worsened considerably 2 years following diagnosis. Maintenance therapy with intravesical BCG was associated with reduced HRQoL, and treatment-related adverse events (AEs) resembled typical NMIBC symptoms. Twenty-two studies reported decreasing BCG compliance over time. Common AEs with BCG were frequent urination, lower urinary tract symptoms, pain, and hematuria. Forty-two publications were included in the economic SLR, of which nine assessed healthcare costs and resource use in NMIBC or bladder cancer. Highrisk disease and high-intensity treatment were associated with increased healthcare costs. Conclusion: NMIBC has a considerable symptomatic, HRQoL, and economic burden. Symptoms persisted and HRQoL worsened despite intravesical BCG treatment. NMIBC is a costly disease, with higher healthcare costs associated with increased risk of disease progression and recurrence. There is a high unmet need for safe and effective treatments that reduce the risk of disease progression and recurrence, provide symptomatic relief, and improve HRQoL for patients.

show abstract

Thiotepa versus Bacille Calmette-Guérin in Non-Muscle Invasive Bladder Cancer

Cited by 6 publications

References 29 publications

Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma

Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma

Semiparametric regression analysis of failure time data with dependent interval censoring

<p>Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews</p>

Contact Info

Product

Resources

About